{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:50:57Z","timestamp":1793407857723,"version":"4.5.0"},"reference-count":171,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The proto-oncogene Rearranged During Transfection (RET) encodes a receptor tyrosine kinase that is essential for neural, renal, and thyroid development. Pathogenic RET alterations, including mutations and fusions, drive oncogenesis, most notably medullary and papillary thyroid carcinomas and non-small cell lung cancer, by constitutively activating downstream RAS\u2013MAPK, PI3K\u2013AKT, and JAK\u2013STAT signaling. Early multi-kinase inhibitors such as vandetanib and cabozantinib demonstrated modest efficacy with significant toxicity, whereas the selective RET inhibitors selpercatinib and pralsetinib have achieved improved response rates and tolerability. However, resistance remains a key clinical challenge, arising from secondary RET mutations and bypass signaling via MET or EGFR pathways. Continued investigation into next-generation inhibitors and rational combination therapies aims to overcome resistance and optimize treatment sequencing, advancing precision oncology for RET-altered malignancies. Nonetheless, resistance, driven by secondary mutations and bypass signaling, presents a major therapeutic challenge. Ongoing development of next-generation inhibitors and combination strategies aims to overcome resistance and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms27073180","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:34:08Z","timestamp":1774974848000},"page":"3180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-2576","authenticated-orcid":false,"given":"Spencer","family":"Streit","sequence":"first","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aala","family":"Dweik","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amen","family":"Mahtab","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Ali","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-9060","authenticated-orcid":false,"given":"Abat","family":"Khan","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzberg","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Memorial Healthcare System, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non\u2013Small Cell Lung Cancer Following Crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2183\/pjab.98.008","article-title":"RET receptor signaling: Function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Regua, A.T., Najjar, M., and Lo, H.W. (2022). RET signaling pathway and RET inhibitors in human cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.932353"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.21037\/tlcr-20-346","article-title":"Decade in review: A new era for RET-rearranged lung cancers","volume":"9","author":"Choudhury","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in Targeting RET-Dependent Cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102153","DOI":"10.1016\/j.ctrv.2021.102153","article-title":"Diagnostics, therapeutics and RET inhibitor resistance for RET fusion\u2013positive non-small cell lung cancers and future perspectives","volume":"96","author":"Lu","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, RET, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"ref_9","first-page":"1378","article-title":"RET transforming gene encodes a fusion protein homologous to tyrosine kinases","volume":"7","author":"Takahashi","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1349-7006.2005.00023.x","article-title":"The RET proto-oncogene: A molecular therapeutic target in thyroid cancer","volume":"96","author":"Kodama","year":"2005","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1006\/bbrc.1993.2392","article-title":"Exon structure and flanking intronic sequences of the human RET proto-oncogene","volume":"196","author":"Ceccherini","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kucharczyk, T., Krawczyk, P., Kowalski, D.M., P\u0142u\u017ca\u0144ski, A., Kubiatowski, T., and Kalinka, E. (2022). RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy. Cancers, 14.","DOI":"10.3390\/cancers14215298"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3934\/Neuroscience.2022008","article-title":"The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung\u2019s disease","volume":"9","author":"Bhattarai","year":"2022","journal-title":"AIMS Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11747","DOI":"10.1021\/acs.jmedchem.0c02167","article-title":"Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development","volume":"64","author":"Saha","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET Proto-oncogene in Cancer and Development","volume":"3","author":"Takahashi","year":"2020","journal-title":"JMA J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mahato, A.K., and Sidorova, Y.A. (2020). RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197108"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mulligan, L.M. (2018). GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.01873"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13058-023-01622-7","article-title":"RET signaling in breast cancer therapeutic resistance and metastasis","volume":"25","author":"Pecar","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_20","unstructured":"Piccaluga, P.P. (2023). RET Proto-Oncogene. Molecular Diagnostics of Cancer, IntechOpen."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors","volume":"27","author":"Links","year":"2006","journal-title":"Endocr. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00441-020-03262-1","article-title":"Intracellular RET signaling pathways activated by GDNF","volume":"382","author":"Kawai","year":"2020","journal-title":"Cell Tissue Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ncponc0610","article-title":"Mechanisms of Disease: Cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy","volume":"3","author":"Drosten","year":"2006","journal-title":"Nat. Clin. Pr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18262","DOI":"10.1074\/jbc.M400505200","article-title":"Tyrosine 981, a novel RET autophosphorylation site, binds c-Src to mediate neuronal survival","volume":"279","author":"Encinas","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.cellsig.2014.03.032","article-title":"Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy","volume":"26","author":"Mologni","year":"2014","journal-title":"Cell Signal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31867","DOI":"10.1074\/jbc.M110.144923","article-title":"Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase","volume":"285","author":"Perrinjaquet","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhao, L., Wang, N., Zhang, D., Jia, Y., and Kong, F. (2023). A comprehensive overview of the relationship between RET gene and tumor occurrence. Front Oncol., 13.","DOI":"10.3389\/fonc.2023.1090757"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"992636","DOI":"10.3389\/fonc.2022.992636","article-title":"Precision oncology for RET-related tumors","volume":"12","author":"Verrienti","year":"2022","journal-title":"Front Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: Expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Desilets, A., Repetto, M., Yang, S.R., Sherman, E.J., and Drilon, A. (2023). RET-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. Cancers, 15.","DOI":"10.3390\/cancers15164146"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/GIM.0b013e318216cc6d","article-title":"Multiple endocrine neoplasia type 2: An overview","volume":"13","author":"Moline","year":"2011","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art Strategies for Targeting RET-Dependent Cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00383-015-3731-y","article-title":"RET gene is a major risk factor for Hirschsprung\u2019s disease: A meta-analysis","volume":"31","author":"Tomuschat","year":"2015","journal-title":"Pediatr. Surg. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"ref_40","first-page":"100037","article-title":"Catalog of 5\u2019 fusion partners in RET+ NSCLC Circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Santoro, M., Moccia, M., Federico, G., and Carlomagno, F. (2020). RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes, 11.","DOI":"10.3390\/genes11040424"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgz184","article-title":"REToma: A cancer subtype with a shared driver oncogene","volume":"41","author":"Kohno","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1758835920928634","DOI":"10.1177\/1758835920928634","article-title":"Current management of RET rearranged non-small cell lung cancer","volume":"12","author":"Stinchcombe","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Klempner","year":"2015","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Platt, A., Morten, J., Ji, Q., Elvin, P., Womack, C., Su, X., Donald, E., Gray, N., Read, J., and Bigley, G. (2015). A RETrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1146-8"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2300295","DOI":"10.1200\/PO.23.00295","article-title":"Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib","volume":"7","author":"Gandhi","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_48","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"25538","DOI":"10.1038\/s41598-024-77663-5","article-title":"Temporal trends of thyroid cancer in China and globally from 1990 to 2021: An analysis of the global burden of Disease Study 2021","volume":"14","author":"Huang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e240297","DOI":"10.1530\/ERC-24-0297","article-title":"Global trends in thyroid cancer 1990\u20132021: An analysis based on the GBD 2021","volume":"32","author":"Deng","year":"2025","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Qiu, Z., Yu, S., Zheng, L., Lou, Y., Chen, X., and Xuan, F. (2025). Global burden of thyroid cancer in adolescents and young adults (aged 15\u201339 years) from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0318605"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-08-2742","article-title":"Targeting the RET pathway in thyroid cancer","volume":"15","author":"Wells","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"T53","DOI":"10.1530\/ERC-17-0297","article-title":"Novel targeted therapeutics for MEN2","volume":"25","author":"Redaelli","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_57","first-page":"1619","article-title":"Somatic mutations of the RET protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence","volume":"81","author":"Romei","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2007.12.016","article-title":"Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas","volume":"284","author":"Dvorakova","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1210\/clinem\/dgac325","article-title":"Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib","volume":"107","author":"Elisei","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.02289","article-title":"RET\/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture","volume":"155","author":"Santoro","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1038\/sj.onc.1206602","article-title":"RET\/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase","volume":"22","author":"Knauf","year":"2003","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/en.2005-0280","article-title":"BRAF mediates RET\/PTC-induced mitogen-activated protein kinase activation in thyroid cells: Functional support for requirement of the RET\/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis","volume":"147","author":"Mitsutake","year":"2006","journal-title":"Endocrinology"},{"key":"ref_65","unstructured":"Baan, R.A., Stewart, B.W., and Straif, K. (2019). Tumour Site Concordance and Mechanisms of Carcinogenesis, IARC Scientific Publications. International Agency for Research on Cancer \u00a9 International Agency for Research on Cancer."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Pitsava, G., Stratakis, C.A., and Faucz, F.R. (2021). PRKAR1A and Thyroid Tumors. Cancers, 13.","DOI":"10.3390\/cancers13153834"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, A., Li, T., Mao, Y.-Y., Gao, M., Shu, S., Xia, C.-H., Dong, Y., Liu, M., Wang, J.-L., and Ma, J.-X. (2024). Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC). BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-03371-5"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1476-4598-13-176","article-title":"KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer","volume":"13","author":"Qian","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, C., Xu, W., Pavlakis, N., Richard, D., and O\u2019Byrne, K. (2019). Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers, 11.","DOI":"10.3390\/cancers11050620"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"188810","DOI":"10.1016\/j.bbcan.2022.188810","article-title":"RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges","volume":"1877","author":"Servetto","year":"2022","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/onc.2010.209","article-title":"Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance","volume":"29","author":"Morandi","year":"2010","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1002\/ijc.29974","article-title":"Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers","volume":"138","author":"Hatem","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jnci\/djy110","article-title":"Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets","volume":"111","author":"Priedigkeit","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_76","unstructured":"Benson, A.B., Venook, A.P., Adam, M., Chang, G., Chen, Y.J., Ciombor, K.K., Cohen, S.A., Cooper, H.S., Deming, D., and Garrido-Laguna, I. (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw., 22."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/onc.2012.225","article-title":"RET is a potential tumor suppressor gene in colorectal cancer","volume":"32","author":"Luo","year":"2013","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.31557\/APJCP.2021.22.4.1019","article-title":"RET Protein Expression in Colorectal Cancer; An Immunohistochemical Assessment","volume":"22","author":"Ashkboos","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.21037\/gs-21-469","article-title":"Case report: Identification of ERC1-RET fusion in a patient with pancreatic ductal adenocarcinoma","volume":"10","author":"Ma","year":"2021","journal-title":"Gland Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-020-01557-3","article-title":"Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer","volume":"39","author":"Guan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: An open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_86","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"key":"ref_87","first-page":"7284","article-title":"ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases1","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1158\/0008-5472.CAN-04-4561","article-title":"ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma","volume":"65","author":"Vidal","year":"2005","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/2159-8290.CD-NB2016-067","article-title":"FDA Approves Drug Combo for Kidney Cancer","volume":"6","author":"Colwell","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","article-title":"FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis","volume":"26","author":"Arora","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/erc.0.0080219","article-title":"Discovery of a novel Raf kinase inhibitor","volume":"8","author":"Lyons","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"29230","DOI":"10.1074\/jbc.M703461200","article-title":"Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting","volume":"282","author":"Mologni","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-07-1772","article-title":"Sorafenib potently inhibits papillary thyroid carcinomas harboring RET\/PTC1 rearrangement","volume":"14","author":"Henderson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_100","first-page":"379","article-title":"FDA approves sorafenib for patients with inoperable liver cancer","volume":"134","author":"Lang","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2015.12.011","article-title":"Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer","volume":"93","author":"Horiike","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"104090","DOI":"10.18632\/oncotarget.22011","article-title":"Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-18-2840","article-title":"Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma","volume":"25","author":"Wu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.12.5.16303","article-title":"Sunitinib inhibits papillary thyroid carcinoma with RET\/PTC rearrangement but not BRAF mutation","volume":"12","author":"Jeong","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.apsb.2014.12.007","article-title":"Alectinib: A novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance","volume":"5","author":"Song","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1535-7163.MCT-14-0274","article-title":"Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non\u2013Small Cell Lung Cancer","volume":"13","author":"Kodama","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jtho.2016.08.126","article-title":"Clinical Activity of Alectinib in Advanced RET-Rearranged Non\u2013Small Cell Lung Cancer","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/tlcr-20-549","article-title":"Phase 1\/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)","volume":"10","author":"Takeuchi","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2022.08.008","article-title":"Alectinib for the treatment of pRETreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial","volume":"172","author":"Felip","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"116340","DOI":"10.1016\/j.bmc.2021.116340","article-title":"New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications","volume":"46","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in Patients with RET Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/onco.13977","article-title":"Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I\/II LIBRETTO-001 Trial","volume":"27","author":"Wirth","year":"2022","journal-title":"Oncologist"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/onco.13976","article-title":"Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I\/II LIBRETTO-001 Trial","volume":"27","author":"Minchom","year":"2022","journal-title":"Oncologist"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: Molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: A Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J. Cancer. Res. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk\/Benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2023.2251398","article-title":"Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: A RETrospective, pharmacovigilance study","volume":"23","author":"Lai","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1097\/MJT.0000000000000306","article-title":"Risk of Gastrointestinal Events During Vandetanib Therapy in Patients with Cancer: A Systematic Review and Meta-analysis of Clinical Trials","volume":"24","author":"Yang","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ijc.28544","article-title":"Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials","volume":"135","author":"Santoni","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00228-017-2299-y","article-title":"Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials","volume":"73","author":"Li","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-023-03362-2","article-title":"Metabolic adverse events of multitarget kinase inhibitors: A systematic review","volume":"81","author":"Acitelli","year":"2023","journal-title":"Endocrine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1210\/jc.2010-2771","article-title":"Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer","volume":"96","author":"Brassard","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Shu, M., Zai, X., Zhang, B., Wang, R., and Lin, Z. (2016). Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147048"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/07357907.2023.2255655","article-title":"Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review","volume":"41","author":"Ali","year":"2023","journal-title":"Cancer Investig."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2, M., La Milia, M., Grassini, M.V., Pugliese, N., De Giorgio, M., and Fagiuoli, S. (2023). Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 15.","DOI":"10.3390\/cancers15061766"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Wang, X., Chen, R., Liu, J., Wang, E., and Luo, H. (2025). Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: A pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database. Expert Opin. Drug Saf., 1\u20139.","DOI":"10.1080\/14740338.2025.2460449"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Xiong, Y., Wang, Q., Liu, Y., Wei, J., and Chen, X. (2022). Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1023660"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e29289","DOI":"10.1097\/MD.0000000000029289","article-title":"Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma","volume":"101","author":"Sasaki","year":"2022","journal-title":"Medicine"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Xue, C., Cui, L., Chen, J., Liu, Y., Deng, Y., Xu, W., Mao, Z., and Wu, J. (2024). Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: A case report and literature review. Front Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1420377"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Wang, X., Yin, D., Tang, Y., Xiao, F., and Wang, S. (2023). Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: A large-scale pharmacovigilance analysis. Front Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1209933"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Mulder, S.F., Bertens, D., Desar, I.M., Vissers, K.C., Mulders, P.F., Punt, C.J., van Spronsen, D.J., Langenhuijsen, J.F., Kessels, R.P., and van Herpen, C.M. (2014). Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: A cross sectional study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-219"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Russo, G., Sorbara, E.E., Cicala, G., Franchina, T., Santarpia, M., Speranza, D., Spina, E., and Silvestris, N. (2023). Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: An analysis from the FDA Adverse Event Reporting System. Front Oncol., 13.","DOI":"10.3389\/fonc.2023.1268672"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.critrevonc.2010.11.007","article-title":"Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials","volume":"80","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2018.07.001","article-title":"Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes","volume":"155","author":"Damaraju","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Chen, M., Shen, J., Jia, R., Chang, M., Zhang, J., Zheng, J., Xue, R., Guo, L., and Yan, K. (2025). Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma. Front Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1487009"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Zou, X., Zhou, P., Lv, W., Liu, C., and Liu, J. (2023). Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review. Front Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1126235"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"Yoon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Onco.L"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/minf.201600039","article-title":"Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer","volume":"35","author":"Meng","year":"2016","journal-title":"Mol. Inform."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Fancelli, S., Caliman, E., Mazzoni, F., Brugia, M., Castiglione, F., Voltolini, L., Pillozzi, S., and Antonuzzo, L. (2021). Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13051091"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Wang, J., Wang, X., Chu, Y., Li, S., and Hao, J. (2025). Predictive factors for efficacy of oxaliplatin-based chemotherapy in advanced well-differentiated neuroendocrine tumors: An observational cohort study and meta-analysis. Front Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1595151"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3349\/ymj.2017.58.1.9","article-title":"EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells","volume":"58","author":"Chang","year":"2017","journal-title":"Yonsei Med. J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-17-0008","article-title":"Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS\/MAPK Signaling","volume":"16","author":"Le","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e2300053","DOI":"10.1200\/PO.23.00053","article-title":"Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients with Metastatic Medullary Thyroid Carcinoma","volume":"7","author":"Hadoux","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"108948","DOI":"10.1016\/j.bioorg.2025.108948","article-title":"Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies","volume":"165","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"#cr-split#-ref_168.1","unstructured":"Nabhan, C., Klink, A., Lee, C.H., Laney, J.R., Yang, Y., and Purdum, A.G. (2023). ASCO Annual Meeting. Proceedings of the Overall Survival"},{"key":"#cr-split#-ref_168.2","unstructured":"(OS) and Transplantation (ASCT) Utilization in Real-World Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL), Chicago, IL, USA, 2-6 June 2023, American Society of Clinical Oncology (ASCO)."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"19536","DOI":"10.1021\/acs.jmedchem.5c01777","article-title":"Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold","volume":"68","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"102372","DOI":"10.1016\/j.ctrv.2022.102372","article-title":"Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies","volume":"105","author":"Pozas","year":"2022","journal-title":"Cancer Treat. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:35:20Z","timestamp":1774974920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":171,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073180"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073180","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}